|
Late last month the Allos drug called "RSR-13" was denied acceptance by the FDA for being inneffectual except for a subset of patients. These patients were Metestatic BC patients who later developed brain mets.
The FDA has allowed Allos to further investigate the effectiveness of this drug. Trials are being held throughout the US and Canada.
Hugs
Christine
|
Linear Mode
